Helixor

What Helixor does

Helixor Heilmittel GmbH is a privately-held German pharmaceutical company founded in 1975 and headquartered in Rosenfeld, Baden-Württemberg, specializing in anthroposophical medicinal products for integrative oncology. The company manufactures injectable mistletoe preparations (Helixor A, M, P) derived from Viscum album on fir, apple tree, and pine hosts, available in ten dosage strengths from 0.01mg to 100mg, alongside Helleborus niger and Helleborus foetidus aqueous dilutions for palliative oncology support, and the Sanomucin nutritional supplement for mucosal barrier health. Production follows anthroposophical manufacturing standards with fresh plant materials processed within hours of harvest, and the company operates under pharmaceutical supervision by Regierungspräsidium Tübingen.

The company generates revenue primarily through one-time sales of prescription and non-prescription medicines distributed via direct pharmacy supply (Apothekendirektbezug) and wholesale channels in Germany, with additional operations in Switzerland through a dedicated country-level team and a distribution partnership in Korea. Its go-to-market combines a regional field sales force targeting oncologists, general practitioners, pharmacists, and complementary medicine practitioners with medical conference participation, E-learning certification programs, the Praxisfinder practitioner locator, and DocCheck-gated professional content. Helixor markets to two primary customer segments: cancer patients seeking complementary therapies to manage chemotherapy side effects such as fatigue and to improve quality of life, and medical professionals who prescribe these therapies as part of integrative oncology protocols. Management is led by Managing Director Markus Struck, with country leadership in Switzerland held by Walter van der Graaf.

Name

Helixor

Legal name

Helixor Heilmittel GmbH

Website

https://helixor.de

Company type

Private

Founded year

1975

Operating status

Operating

Headcount range

101–250 employees

Short description

Helixor Heilmittel GmbH is a German pharmaceutical company that manufactures anthroposophical mistletoe and hellebore injectables, plus the Sanomucin supplement, for cancer patients and prescribing clinicians in Germany, Switzerland, and Korea.

Ownership category

akta.pro rank

Headquarters

HQ city

Rosenfeld

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Helixor generates revenue through the sale of prescription and non-prescription anthroposophical medicines, primarily mistletoe preparations (Helixor A, M, P) and Helleborus therapies. Products are sold directly to pharmacies and through wholesale distribution channels. The company also offers nutritional supplements like Sanomucin.
2. Pharmacy Direct Supply: Direct supply relationship with pharmacies (Apothekendirektbezug) where Helixor delivers products directly. This channel involves specific return policies and refund arrangements of up to 70% of purchase price for products with at least 3 months before expiration.
3. International Distribution: Export and distribution of products internationally, including operations in Switzerland and Korea. The company maintains international partnerships for broader geographic reach.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Helixor develops, manufactures and distributes anthroposophical injectable medicines for integrative oncology, primarily Helixor A, M and P mistletoe preparations (Viscum album) in 10 dosage strengths from 0.01mg to 100mg, Helleborus niger and Helleborus foetidus dilutions for palliative oncology support, and the Sanomucin nutritional supplement for mucosal barrier health. Products are produced in-house at the company's Rosenfeld facility and reach patients via pharmacies, wholesale distributors, and a dedicated Swiss subsidiary, supported by free therapy consultation, E-learning certification for healthcare professionals and a Praxisfinder practitioner directory.

Product overview

Helixor is a pharmaceutical company specializing in integrative oncology, offering a portfolio of anthroposophical medicinal products centered around three main therapy approaches: Misteltherapie (Mistletoe Therapy), Helleborustherapie (Helleborus Therapy), and Sanomucin. The core products include Helixor® A, M, P injection solutions in various strengths derived from mistletoe extracts (Viscum album), as well as Helleborus niger aquos. and Helleborus foetidus aquos. homeopathic dilutions. The company provides these complementary cancer therapies alongside conventional oncology treatments to improve patient quality of life, reduce treatment side effects, and support the immune system.

Differentiator

Problem solved

Functional benefit

Brands

• Helixor A, M, P: Mistletoe injection solutions in various strengths for integrative oncology treatment
• Helleborus niger aquos.
• Helleborus foetidus aquos.
• Sanomucin

Products and services

• Helixor A, M, P Mistletoe Injection Solutions Injectable prescription anthroposophical medicine derived from fresh mistletoe (Viscum album) herb harvested from three host-tree variants — Helixor A from fir, Helixor M from apple tree and Helixor P from pine — at a 1:20 plant-to-extract ratio. Available in 10 dosage strengths from 0.01mg to 100mg for subcutaneous injection, used by oncologists, GPs, pharmacists and complementary medicine practitioners to improve quality of life, reduce cancer-related fatigue, support immune function and reduce side effects during chemotherapy.
• Helleborus niger aquos. Injection Solution Liquid dilution for injection registered as a homeopathic medicine of the anthroposophical therapy direction, containing extracts of Helleborus niger (black hellebore / Christmas rose) flowers and whole plant. Used in palliative tumor situations to provide calm, anxiety relief and reduced restlessness in oncology patients.
• Helleborus foetidus aquos. Injection Solution Liquid dilution for injection registered as a homeopathic medicine of the anthroposophical therapy direction, containing extracts of Helleborus foetidus (stinking hellebore) flowers, leaf and root. Used in palliative tumor situations as part of Helixor's broader hellebore-based therapy approach for oncology patients experiencing anxiety and severe restlessness.
• Sanomucin Mucosal Support Nutritional Supplement Non-prescription oral nutrient combination containing plant compounds, vitamins, biotin and selenium formulated to support the natural mucosal barrier of the body, which forms part of the immune defence. Biotin contributes to the maintenance of normal mucous membranes. Marketed primarily to oncology patients and other consumers seeking mucosal health support, available in a new format launch communicated on the Helixor website.

Quantifiable outcome

• More than two-thirds of cancer patients in Germany trust mistletoe therapy
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Korean Distribution PartnercoreChannel Partner/ Reseller/ Distributor · 1 January 2023Korean distribution partner visited Helixor headquarters in October 2023 with Korean press representatives to learn about mistletoe therapy and tour the facility including the mistletoe garden. This represents Helixor's international expansion efforts.
• Filderklinik (Center for Integrative Oncology)coreStrategic or Co-development PartnerLeading integrative oncology clinic in Germany where mistletoe therapy has become standard practice. Dr. med. Stefan Hiller serves as Chief Physician and frequently collaborates with Helixor on patient seminars and educational content about complementary cancer therapy.
• Zentrum für Integrative Onkologie ZürichminorStrategic or Co-development PartnerDr. med. Boris Hübenthal serves as Medical Director and has collaborated on educational content about integrative oncology approaches including mistletoe therapy.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Roche: Global oncology giant headquartered in Switzerland with broad franchises in cancer therapeutics and supportive care. Overlaps with Helixor's prescriber base of oncologists in DACH and Switzerland but operates at vastly different scale and across the conventional oncology paradigm.
• AstraZeneca: Global oncology and supportive-care major with significant European presence. Comparable as a broad incumbent serving the same oncologist and supportive-care prescriber universe as Helixor, but at mainstream-pharma scale.
• Novartis: Major Swiss-headquartered oncology and supportive-care pharmaceutical company. Relevant as a large incumbent with overlapping Swiss/DACH physician relationships and complementary supportive-care offerings for cancer patients.
• Mundipharma International: Global specialty pharma with strong oncology supportive-care and pain-management franchises. Competes with Helixor in addressing cancer-related symptoms but as part of a broader, larger portfolio rather than a focused anthroposophical niche.

Direct peers

• WALA Heilmittel GmbH: Anthroposophical medicines manufacturer based in Bad Boll/Eckwälden producing injectable and oral remedies from natural substances. Shares Helixor's anthroposophical-pharma DNA and physician-channel distribution model, with overlapping oncology and general practice lines.
• Hiscia Institute for Applied Tumour Biology: Swiss producer of Iscador / Helixor-style mistletoe preparations (e.g., Viscum album extracts) for complementary oncology. Direct peer in the anthroposophical injectable mistletoe segment, operating across Switzerland and select international markets.
• Weleda AG: Anthroposophical pharmaceutical and natural cosmetics company with comparable injectable and oral remedies. Overlaps Helixor in anthroposophical prescription medicines and shares the same practitioner training and conference engagement strategy.
• Iscador AG: Swiss/German manufacturer of Iscador mistletoe preparations (M, P, Qu) for integrative oncology. The closest direct competitor to Helixor's mistletoe therapy portfolio with overlapping hospital, physician, and pharmacy channels in DACH.
• Abnoba Heilmittel GmbH: German pharmaceutical manufacturer specializing in Abnoba viscum mistletoe extracts for oncology. Competes head-to-head with Helixor in the same physician-prescribed, pharmacy-distributed injectable category in Germany.

Regional players

• Daiichi Sankyo: Japanese pharmaceutical major with growing oncology and supportive-care franchises in Asia, including Korea. Relevant as a regional incumbent in the same Korean market where Helixor operates via its distribution partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCJSq5Du8aH0o2wObX2LwSlw
• Facebookfacebook.com/Helixor
• LinkedInlinkedin.com/company/helixor-heilmittel-gmbh
• Instagraminstagram.com/helixorheilmittel

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helixor